- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02175849
Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis (SNAP)
Contact Tracing by Social Network Analysis to Enhance Multi-Drug Resistant Tuberculosis Case Finding in Hanoi, Vietnam
Tuberculosis burden in Vietnam increasing with contribution from low detection rates and increased drug resistance. There is a need to identify MDR-TB (MultiDrug Resistant Tuberculosis) among both notified TB cases and their contacts in the community. Traditional contact tracing often focuses on household contacts while strains of TB circulate in homes, schools, workplaces, and beyond. Social network Analysis (SNA) is a comprehensive approach which includes a set of persons and the connections among them used for analysis of structure of disease transmission.
In this study, SNA will be used to collect network data from 60 newly detected Rifampicin resistant TB patients including an expected 50 MDR-TB patients living in Hanoi, and to identify and test potential MDR-TB cases.
연구 개요
상태
정황
상세 설명
The study will identify and recruit 60 newly detected Rifampicin resistant TB patients including an expected 50 MDR-TB patients living in Hanoi (index cases) who will undergo SNA of contacts and places they have stayed during 3 months preceding their TB diagnosis including residence, travel history, places of social aggregation in relation with their risk behaviour.
Patients will be interviewed to investigate contacts before the confirmation of MDR-TB (for early contact detection and minimize the risk of information lost due to patient default during treatment). Data analysis will focus on MDR-TB social networks using Cytoscape software.
After the first two enrolled Rifampicin resistant MDR-TB cases, social network data will be analyzed to identify close contacts, mutual contacts, mutual places and high risk locations. The Social Network Questionnaire (SNQ) will be contextualized to the Vietnamese setting and validated in a pilot study. Eligible contacts and locations will undergo MDR-TB screening.
Approximately 720 contacts will undergo active screening (on 2 occasions per individual: at the time of contact identification and 6 months later). Contacts will include household contacts, close contacts, mutual contacts and symptomatic individuals with significant exposure to the index case at mutual locations within a closed environment.
Contact screening will involve clinical assessment, chest X-ray and sputum or gastric aspirate collection for TB culture, molecular techniques and microbiological identification.
If contacts are screened and detected as having Rifampicin resistant TB, they will be invited to be included in SNA for further analysis.
The number of MDR-TB detected by SNA will determine whether transmission of MDR-TB not otherwise detected by routine contact investigation (only household contact tracing) is important. While traditional contact tracing practices in Vietnam mainly focus on household contacts to detect secondary cases of TB, this SNA is expected not only to identify secondary cases of MDR-TB within an extended catchment but to also identify the source cases of MDR-TB patients to " turn off the tap" of MDR-TB transmission. Moreover, the places identified as the sources of sustained transmission will be targeted for case finding along with appropriate resource allocation.
In this study analysis will focus on the costs of contact tracing with Social Network Questionnaires, the proportion of MDR-TB among eligible contacts by subgroup, the proportion of MDR-TB among Rifampicin resistant TB patients and the genotyping pattern of MDR -TB patients.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Hanoi, 베트남, 10000
- National Lung Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- PATIENTS: Newly detected rifampicin resistant TB or MDR-TB patients living in Hanoi for at least 3 months preceding a diagnosis made between 2013-2015.
- CONTACTS: During the 3 months before the patient's TB or MDR-TB diagnosis: all persons who spend an average of >4 hours per day in the same residence as the patient AND/OR any individual who has had frequent and prolonged contact with the patient AND/OR anyone who has spent time in a closed environment with an MDR-TB patient
- PATIENTS AND CONTACTS: All ages
- PATIENTS AND CONTACTS: Living in Hanoi during the study period.
Exclusion Criteria:
-PATIENTS AND CONTACTS: Lack of informed consent for participation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
---|
Drug resistant TB patients
Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
|
Contacts
Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Yield of MDR-TB case detection through SNA
기간: Six months
|
The number of MDR-TB cases notified from contacts identified by SNA and who would not have been detected by routine screening.
|
Six months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
MDR-TB incidence among subgroups of contacts
기간: Six months
|
The proportion of MDR-TB among eligible contacts by subgroup (household contacts, close contacts, mutual contacts, eligible contacts from mutual places with closed environment).
|
Six months
|
MDR-TB incidence among rifampicin resistant TB cases
기간: Six months
|
Incidence of MDR-TB confirmed by drug susceptibility tests (DST) among rifampicin resistant TB patients.
|
Six months
|
MDR-TB genotype
기간: Six months
|
Consistency or difference between TB genotype of enrolled MDR-TB patients and contacts/secondary cases.
|
Six months
|
Cost-effectiveness ratio of SNA and passive case finding strategies
기간: Six months
|
The incremental cost-effectiveness ratio (ICERs) between SNA and passive case finding for one MDR-TB case detected (i.e, the cost of SNA minus the cost of passive case finding divided by the yield in terms of case detection of SNA minus the yield of passive CF)
|
Six months
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 10TB
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
결핵 감염에 대한 임상 시험
-
François SpertiniUniversity of Oxford완전한
-
Assistance Publique - Hôpitaux de Paris완전한